Subcutaneous semaglutide more than doubles the likelihood of NASH resolution without fibrosis progression
Semaglutide shows promise for treating fatty liver disease and NASH
This meta-analysis of randomized controlled trials evaluated subcutaneous semaglutide in adults with NAFLD or NASH. The analysis found signi…
A new analysis shows that semaglutide can help resolve liver inflammation and improve metabolic health in people with fatty liver disease.
Cagrilintide-semaglutide reduces HbA1c by up to 2.33% in adults with type 2 diabetes
New insulin combination shows promise for managing type 2 diabetes
This Phase 3a randomized controlled trial of 274 adults with type 2 diabetes found that adding cagrilintide-semaglutide to basal insulin sig…
A new drug combination added to daily insulin helps lower blood sugar and body weight in adults with type 2 diabetes.
Semaglutide significantly reduces BMI and improves hypertension control in patients with obesity and CKD
Semaglutide Shows Significant Benefits for Weight Loss and Kidney Health
This meta-analysis of 430 patients found that semaglutide leads to significant BMI reduction, improved hypertension control (P < 0.02), and …
New research highlights how semaglutide effectively reduces BMI and improves renal function in patients with obesity and chronic kidney dise…
Incretin-based therapies outperform placebo for glycemic control and weight loss in type 2 diabetes
Newer diabetes drugs outperform for blood sugar and weight loss
This network meta-analysis of 15 incretin-based therapies (IBTs) indicates that tirzepatide, orforglipron, and semaglutide provide superior …
A large analysis finds that newer incretin-based drugs like tirzepatide and semaglutide beat placebo for blood sugar and weight loss in type…
Evolocumab reduces MACE by 29% in patients with BMI greater than or equal to 35 kg/m
Evolocumab shows greater heart protection for patients with higher BMI
This randomized controlled trial of 27,564 stable atherosclerotic cardiovascular disease patients found that evolocumab significantly reduce…
A large study finds that the heart medication evolocumab provides significantly more protection against heart attacks and strokes for patien…
Semaglutide reduces risk of kidney decline or death in type 2 diabetes and CKD
Semaglutide lowers kidney and heart risks in type 2 diabetes patients
This randomized controlled trial enrolled 3,533 participants with type 2 diabetes and chronic kidney disease. Once-weekly subcutaneous semag…
A large trial shows once-weekly semaglutide reduces kidney failure and death risks in people with type 2 diabetes and chronic kidney disease…
Semaglutide associated with 35.2% of weight loss as lean mass versus 26.2% with lifestyle interventions
New analysis shows weight loss drugs and lifestyle changes affect muscle loss similarly
This systematic review and meta-analysis evaluated 15 782 adults with overweight or obesity receiving incretin-based therapies or intensive …
A large review of 15,782 adults found that weight loss drugs and lifestyle changes led to similar proportions of muscle loss during weight r…
Semaglutide use may be associated with kidney damage in 20 cases across 18 studies
Semaglutide may harm kidneys in rare cases, doctors warn
This systematic review synthesizes data from 18 studies involving 20 cases of kidney injury linked to semaglutide. Among these cases, 17 pat…
A review of 20 cases found that semaglutide use was linked to kidney injury, with most patients recovering but some not.
Tirzepatide maximum tolerated dose leads weight reduction ranking in obesity network meta-analysis
New analysis shows weight loss drugs work best for adults with obesity without diabetes
This systematic review and network meta-analysis of 14,059 adults with obesity without diabetes ranked GLP-1 receptor agonists and a dual ag…
A large review of many studies found that specific injectable medicines help adults lose weight. Tirzepatide worked best, but all options re…
Semaglutide Improves Metabolic Health in Schizophrenia Patients on Antipsychotics
Semaglutide improves blood sugar and weight in people with schizophrenia and prediabetes
A randomized, placebo-controlled trial in 154 overweight or obese individuals with schizophrenia and prediabetes receiving second-generation…
A new trial shows semaglutide helps lower blood sugar and reduce weight in people with schizophrenia who also have prediabetes or obesity.
GLP-1 receptor agonists show no increased ocular disorder risk in type 2 diabetes meta-analysis
New analysis shows GLP-1 drugs do not raise eye disease risk for diabetes patients
This systematic review and meta-analysis of 28 observational studies found that GLP-1 receptor agonists did not increase the risk of NAION, …
A large review of 28 studies found that diabetes drugs called GLP-1 receptor agonists do not increase the risk of eye problems like glaucoma…
Semaglutide 1.7 mg shows comparable BMI reduction to 2.4 mg in adolescents and adults
Lower-dose semaglutide works as well as higher doses for teen and adult obesity
This model-informed analysis combined Phase 3 adolescent and adult semaglutide trial data. Semaglutide 1.7 mg produced a mean BMI change com…
A new analysis shows that a lower dose of semaglutide works just as well as the higher dose for weight loss in teens and adults, with simila…